Melvin Olson

2.6k total citations · 1 hit paper
34 papers, 2.0k citations indexed

About

Melvin Olson is a scholar working on Orthopedics and Sports Medicine, Oncology and Economics and Econometrics. According to data from OpenAlex, Melvin Olson has authored 34 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Orthopedics and Sports Medicine, 8 papers in Oncology and 7 papers in Economics and Econometrics. Recurrent topics in Melvin Olson's work include Bone health and osteoporosis research (13 papers), Bone and Joint Diseases (9 papers) and Bone health and treatments (7 papers). Melvin Olson is often cited by papers focused on Bone health and osteoporosis research (13 papers), Bone and Joint Diseases (9 papers) and Bone health and treatments (7 papers). Melvin Olson collaborates with scholars based in Switzerland, United States and Netherlands. Melvin Olson's co-authors include Tjeerd van Staa, Cyrus Cooper, Bo Abrahamsen, Rinat Ariely, M. Azria, Linda Mindeholm, Fernie J. A. Penning‐van Beest, Ron M. C. Herings, Stephan Rietbrock and Joëlle A. Erkens and has published in prestigious journals such as PLoS ONE, Neurology and Journal of Bone and Mineral Research.

In The Last Decade

Melvin Olson

34 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Excess mortality following hip fracture: a systematic epidemiological review

2009 828 citations Bo Abrahamsen, Tjeerd van Staa et al. Osteoporosis International profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Melvin Olson Switzerland	17	988	884	514	302	255	34	2.0k
Michel Boucher France	16	708 0.7×	467 0.5×	460 0.9×	336 1.1×	286 1.1×	100	1.7k
Rita L. Hui United States	18	668 0.7×	316 0.4×	737 1.4×	140 0.5×	274 1.1×	66	2.3k
Dima L. Diab United States	12	1.1k 1.1×	472 0.5×	696 1.4×	430 1.4×	77 0.3×	20	1.8k
William J. Huster United States	21	686 0.7×	288 0.3×	1.2k 2.3×	795 2.6×	88 0.3×	45	3.6k
W. Dere United States	17	446 0.5×	285 0.3×	278 0.5×	311 1.0×	60 0.2×	35	1.6k
Alice Dragomir Canada	27	156 0.2×	663 0.8×	300 0.6×	174 0.6×	484 1.9×	95	2.2k
Xiang Fang China	25	189 0.2×	735 0.8×	156 0.3×	361 1.2×	498 2.0×	126	2.1k
Barbara Mason New Zealand	21	1.1k 1.1×	289 0.3×	393 0.8×	278 0.9×	119 0.5×	36	2.4k
Haojie Li China	27	109 0.1×	684 0.8×	912 1.8×	1.0k 3.4×	134 0.5×	137	3.8k
Simon Cawthorn United Kingdom	23	205 0.2×	797 0.9×	1.7k 3.3×	305 1.0×	69 0.3×	54	3.6k

Countries citing papers authored by Melvin Olson

Since Specialization

Citations

This map shows the geographic impact of Melvin Olson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melvin Olson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melvin Olson more than expected).

Fields of papers citing papers by Melvin Olson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melvin Olson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melvin Olson. The network helps show where Melvin Olson may publish in the future.

Co-authorship network of co-authors of Melvin Olson

This figure shows the co-authorship network connecting the top 25 collaborators of Melvin Olson. A scholar is included among the top collaborators of Melvin Olson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melvin Olson. Melvin Olson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zullig, Leah L., Connor Drake, Devon K. Check, et al.. (2023). Embedding implementation science in the research pipeline. Translational Behavioral Medicine. 14(2). 73–79. 10 indexed citations

Goto, Daisuke, Ya‐Chen Tina Shih, Pascal Lecomte, et al.. (2017). Regression-Based Approaches to Patient-Centered Cost-Effectiveness Analysis. PharmacoEconomics. 35(7). 685–695. 8 indexed citations

Goto, Daisaku, et al.. (2016). A LITERATURE REVIEW OF FACTORS AFFECTING PRICE AND COMPETITION IN THE GLOBAL PHARMACEUTICAL MARKET. Value in Health. 19(3). A265–A265. 5 indexed citations

Naujoks, Christel, et al.. (2016). How do Migraines Impact Patient Day-To-Day life? An Exploratory Analysis of Patient Reported Data From The Patientslikeme Community. Value in Health. 19(7). A438–A439. 2 indexed citations

Ivanov, Vladimir N., Eric Tchetgen Tchetgen, Bruce W. Church, et al.. (2016). Using Clinical Trial and Real World Data to Bridge Efficacy to Effectiveness of Fingolimod in Multiple Sclerosis Patients. Value in Health. 19(7). A426–A426. 1 indexed citations

Bonzani, Ian C., et al.. (2016). Patterns of Treatment Switching in Multiple Sclerosis Therapies in US Patients Active on Social Media: Application of Social Media Content Analysis to Health Outcomes Research. Journal of Medical Internet Research. 18(3). e62–e62. 33 indexed citations

Bonzani, Ian C., et al.. (2016). Linked Patient-Reported Outcomes Data From Patients With Multiple Sclerosis Recruited on an Open Internet Platform to Health Care Claims Databases Identifies a Representative Population for Real-Life Data Analysis in Multiple Sclerosis. Journal of Medical Internet Research. 18(9). e249–e249. 5 indexed citations

Bonzani, Ian C., et al.. (2015). Validation of Social Media Analysis for Outcomes Research: Identification of Drivers of Switches between oral and Injectable Therapies for Multiple Sclerosis. Value in Health. 18(7). A729–A729. 3 indexed citations

Jónsson, Páll, et al.. (2015). Stakeholder Views On The Acceptability Of Real-World Evidence For Informing Trial Design And Assessment Of Relative Effectiveness Of New Medicines. Value in Health. 18(7). A685–A685. 1 indexed citations

10.

Ferreira, Alberto, et al.. (2015). Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA. PLoS ONE. 10(7). e0133968–e0133968. 51 indexed citations

11.

Sambrook, Philip N., Stuart L. Silverman, Jane A. Cauley, et al.. (2011). Health-related quality of life and treatment of postmenopausal osteoporosis: Results from the HORIZON-PFT. Bone. 48(6). 1298–1304. 15 indexed citations

12.

Jansen, Jeroen P., Gert Bergman, Jasper Huels, & Melvin Olson. (2010). The Efficacy of Bisphosphonates in the Prevention of Vertebral, Hip, and Nonvertebral-Nonhip Fractures in Osteoporosis: A Network Meta-Analysis. Seminars in Arthritis and Rheumatism. 40(4). 275–284.e2. 88 indexed citations

13.

Abrahamsen, Bo, Tjeerd van Staa, Rinat Ariely, Melvin Olson, & Cyrus Cooper. (2009). Excess mortality following hip fracture: a systematic epidemiological review. Osteoporosis International. 20(10). 1633–1650. 828 indexed citations breakdown →

14.

Jansen, Jeroen P., Gert Bergman, Jasper Huels, & Melvin Olson. (2009). Prevention of vertebral fractures in osteoporosis: mixed treatment comparison of bisphosphonate therapies. Current Medical Research and Opinion. 25(8). 1861–1868. 33 indexed citations

15.

Rietbrock, Stephan, Melvin Olson, & Tjeerd van Staa. (2008). The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates. QJM. 102(1). 35–42. 26 indexed citations

16.

Meijer, Willemijn M., Fernie J. A. Penning‐van Beest, Melvin Olson, & Ron M. C. Herings. (2008). Relationship between duration of compliant bisphosphonate use and the risk of osteoporotic fractures. Current Medical Research and Opinion. 24(11). 3217–3222. 18 indexed citations

17.

Chesnut, C. H., M. Azria, Stuart L. Silverman, et al.. (2007). Salmon calcitonin: a review of current and future therapeutic indications. Osteoporosis International. 19(4). 479–491. 162 indexed citations

18.

Beest, Fernie J. A. Penning‐van, Joëlle A. Erkens, Melvin Olson, & Ron M. C. Herings. (2007). Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporosis International. 19(4). 511–517. 113 indexed citations

19.

Matchaba, Patrice, Xavier Gitton, Gerhard Krammer, et al.. (2005). Cardiovascular safety of lumiracoxib: A meta-analysis of all randomized controlled trials ≥1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis. Clinical Therapeutics. 27(8). 1196–1214. 44 indexed citations

20.

Bagger, Yu Z., László B. Tankó, Peter Alexandersen, et al.. (2005). Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: A new potential treatment of osteoarthritis. Bone. 37(3). 425–430. 87 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact